GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Operating Margin %

Karo Pharma AB (Karo Pharma AB) Operating Margin % : 0.00% (As of Jun. 2022)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Karo Pharma AB's Operating Income for the three months ended in Jun. 2022 was $0.0 Mil. Karo Pharma AB's Revenue for the three months ended in Jun. 2022 was $0.0 Mil. Therefore, Karo Pharma AB's Operating Margin % for the quarter that ended in Jun. 2022 was 0.00%.

The historical rank and industry rank for Karo Pharma AB's Operating Margin % or its related term are showing as below:


KARBF's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.29
* Ranked among companies with meaningful Operating Margin % only.

Karo Pharma AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Karo Pharma AB's Operating Income for the three months ended in Jun. 2022 was $0.0 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2022 was $23.7 Mil.


Karo Pharma AB Operating Margin % Historical Data

The historical data trend for Karo Pharma AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Operating Margin % Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.64 25.85 10.65 8.67 6.73

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.98 4.16 13.47 -7.81 -

Competitive Comparison of Karo Pharma AB's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karo Pharma AB's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's Operating Margin % falls into.



Karo Pharma AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Karo Pharma AB's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=21.913 / 325.796
=6.73 %

Karo Pharma AB's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=0 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karo Pharma AB  (OTCPK:KARBF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Karo Pharma AB Operating Margin % Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (Karo Pharma AB) Business Description

Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire 06-25-2019